{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:30:45Z","timestamp":1771867845130,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2003,7]]},"DOI":"10.1124\/dmd.31.7.955","type":"journal-article","created":{"date-parts":[[2003,6,18]],"date-time":"2003-06-18T16:30:16Z","timestamp":1055953816000},"page":"955-966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["CYTOCHROME P450 INHIBITION USING RECOMBINANT PROTEINS AND MASS SPECTROMETRY\/MULTIPLE REACTION MONITORING TECHNOLOGY IN A CASSETTE INCUBATION"],"prefix":"10.1016","volume":"31","author":[{"given":"Richard","family":"Weaver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken S.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain G.","family":"Beattie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob J.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.31.7.955_bib1","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1124\/dmd.30.12.1497","article-title":"The influence of nonspecific microsomal binding on apparent intrinsic clearance and its prediction from physicochemical properties.","volume":"30","author":"Austin","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1097-0231(19980314)12:5<217::AID-RCM146>3.0.CO;2-I","article-title":"Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 substrates.","volume":"12","author":"Ayrton","year":"1998","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1124\/dmd.31.7.955_bib3","doi-asserted-by":"crossref","first-page":"12582","DOI":"10.1021\/bi980674a","article-title":"Interactions among P450 enzymes when combined in reconstituted systems: formation of a 2B4\u20131A2 complex with a high affinity for NADPH-cytochrome P450 reductase.","volume":"37","author":"Backes","year":"1998","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.31.7.955_bib4","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1023\/A:1007665310830","article-title":"A population approach to enzyme characterization and identification: application to phenacetin O-deethylation.","volume":"17","author":"Belle","year":"2000","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/dmd.31.7.955_bib5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO;2-0","article-title":"The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds.","volume":"13","author":"Bonfiglio","year":"1999","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1124\/dmd.31.7.955_bib6","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0006-2952(93)90272-X","article-title":"Fluvoxamine is a potent inhibitor of cytochrome P4501A2.","volume":"45","author":"Br\u00f8sen","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.31.7.955_bib7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/rcm.290","article-title":"High Throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy.","volume":"15","author":"Bu","year":"2001","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1124\/dmd.31.7.955_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/(SICI)1097-0231(20000229)14:4<207::AID-RCM863>3.0.CO;2-#","article-title":"Validation of higher-throughput high-performance liquid chromatography \/ atmospheric pressure chemical ionisation tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and 3A4 enzyme inhibition studies in human liver microsomes.","volume":"14","author":"Chu","year":"2000","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1124\/dmd.31.7.955_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1054-3589(08)60205-7","article-title":"Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions.","volume":"43","author":"Crespi","year":"1997","journal-title":"Adv Pharmacol"},{"key":"10.1124\/dmd.31.7.955_bib10","first-page":"23","article-title":"A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass-spectrometry.","volume":"29","author":"Dierks","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2125.1998.00679.x","article-title":"Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.","volume":"45","author":"Eagling","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.31.7.955_bib12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF00314987","article-title":"In vitro forecasting of drugs which may interfere with the biotransformation of midazolam.","volume":"41","author":"Gascon","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.31.7.955_bib13","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0006-2952(94)90543-6","article-title":"Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.","volume":"47","author":"Gorski","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.31.7.955_bib14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1600-0773.1995.tb00144.x","article-title":"Kinetics and inhibition by fluvoxamine of phenacetin O-deethylation in V79 cells expressing human CYP1A2.","volume":"76","author":"Jensen","year":"1995","journal-title":"Pharmacol Toxicol"},{"key":"10.1124\/dmd.31.7.955_bib15","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0090-9556(24)15234-8","article-title":"Involvement of CYP2E1 as a low affinity enzyme in phenacetin O-deethylation in human liver microsomes.","volume":"27","author":"Kobayashi","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0026-895X(25)09118-7","article-title":"Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.","volume":"36","author":"Kronbach","year":"1989","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.31.7.955_bib17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0006-2952(00)00335-X","article-title":"On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics.","volume":"60","author":"Lewis","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.31.7.955_bib18","first-page":"368","article-title":"Substrate inhibition kinetics for cytochrome P450-catalyzed reactions.","volume":"29","author":"Lin","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib19","doi-asserted-by":"crossref","first-page":"16205","DOI":"10.1021\/bi961950t","article-title":"Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: Particular efficiency and regioselectivity of P450 2Cs.","volume":"35","author":"Mancy","year":"1999","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.31.7.955_bib20","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0090-9556(24)15021-0","article-title":"The role of CYP2C19 in the metabolism of (+\/\u2013) bufuralol, the prototypic substrate of CYP2D6.","volume":"27","author":"Mankowski","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib21","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0090-9556(24)15034-9","article-title":"Heterologous expression and kinetic characterization of human cytochromes P-450: Validation of a pharmaceutical tool for drug metabolism research.","volume":"27","author":"Masimirembwa","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0090-9556(24)15020-9","article-title":"Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in","volume":"27","author":"McGinnity","year":"1999","journal-title":"Escherichia coli. Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0090-9556(24)15081-7","article-title":"Automated definition of the enzymology of drug oxidation by the major human drug metabolising cytochrome P450s.","volume":"28","author":"McGinnity","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/004982599238812","article-title":"Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential.","volume":"29","author":"Moody","year":"1999","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.31.7.955_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1570-0232(02)00142-3","article-title":"Ion suppression effects in liquid chromatography-electrospray-ionisation transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries.","volume":"773","author":"M\u00fcller","year":"2002","journal-title":"J Chromatog B: Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.31.7.955_bib26","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0090-9556(24)15184-7","article-title":"Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine.","volume":"28","author":"Ngui","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib27","first-page":"1359","article-title":"Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranolol.","volume":"25","author":"Obach","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib28","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0022-3565(24)35332-7","article-title":"Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.","volume":"292","author":"Perloff","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.31.7.955_bib29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/03602539709037591","article-title":"Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors.","volume":"29","author":"Rendic","year":"1997","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.31.7.955_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1056-8719(97)00103-2","article-title":"In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin.","volume":"38","author":"Riley","year":"1998","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/dmd.31.7.955_bib31","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0090-9556(25)06730-3","article-title":"Induction of rodent hepatic drug-metabolizing enzyme activities by the novel anticonvulsant remacemide hydrochloride.","volume":"23","author":"Riley","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib32","first-page":"1097","article-title":"[O-ethyl 14C]phenacetin O-deethylase activity in human liver microsomes.","volume":"25","author":"Rodrigues","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/004982500237541","article-title":"Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450.","volume":"30","author":"Sai","year":"2000","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.31.7.955_bib34","first-page":"70","article-title":"Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site.","volume":"29","author":"Schrag","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib35","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1021\/tx9802365","article-title":"Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac.","volume":"12","author":"Shen","year":"1999","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.31.7.955_bib36","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.31.7.955_bib37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1042\/bj3310783","article-title":"Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity.","volume":"331","author":"Smith","year":"1998","journal-title":"Biochem J"},{"key":"10.1124\/dmd.31.7.955_bib38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1006\/abbi.1997.9995","article-title":"Competitive interactions between cytochromes P450 2A6 and 2E1 for NADPH-cytochrome P450 oxoreductase in the microsomal membranes produced be a baculovirus expression system.","volume":"342","author":"Tan","year":"1997","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.31.7.955_bib39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/tx9802217","article-title":"Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.","volume":"12","author":"Tang","year":"1999","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.31.7.955_bib40","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1021\/js980255z","article-title":"Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity.","volume":"87","author":"Venkatakrishnan","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.31.7.955_bib41","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0090-9556(24)14965-3","article-title":"CYP2C9 is a principal low-affinity phenacetin O-deethylase: fluvoxamine is not a specific CYP1A2 inhibitor.","volume":"27","author":"Venkatakrishnan","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib42","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/j.1552-4604.1996.tb04251.x","article-title":"Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine and by azole antifungal agents.","volume":"36","author":"von Moltke","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.31.7.955_bib43","first-page":"110","article-title":"Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally.","volume":"26","author":"Wandel","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.31.7.955_bib44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/abbi.1997.0125","article-title":"Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: Effects of cytochrome P450\u2013P450 and cytochrome P450-b5 interactions.","volume":"342","author":"Yamazaki","year":"1997","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.31.7.955_bib45","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0006-2952(98)00133-6","article-title":"Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen and diclofenac by human liver microsomes.","volume":"56","author":"Yamazaki","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.31.7.955_bib46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/004982500237749","article-title":"Automated high throughput human CYP isoform activity assay using SPE-LC\/MS method: application in CYP inhibition evaluation.","volume":"30","author":"Yin","year":"2000","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.31.7.955_bib47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1006\/abio.2001.5383","article-title":"Quantitative liquid chromatography\/mass spectrometry\/mass spectrometry warfarin assay for in vitro cytochrome P450 studies.","volume":"298","author":"Zhang","year":"2001","journal-title":"Anal Biochem"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624027284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624027284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.31.7.955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T15:11:52Z","timestamp":1739891512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624027284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["S0090955624027284"],"URL":"https:\/\/doi.org\/10.1124\/dmd.31.7.955","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2003,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYTOCHROME P450 INHIBITION USING RECOMBINANT PROTEINS AND MASS SPECTROMETRY\/MULTIPLE REACTION MONITORING TECHNOLOGY IN A CASSETTE INCUBATION","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.31.7.955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2003 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}